Phoenix Wealth Advisors Sells 56 Shares of Danaher Co. (NYSE:DHR)

Phoenix Wealth Advisors lessened its position in shares of Danaher Co. (NYSE:DHR) by 1.3% in the fourth quarter, HoldingsChannel reports. The fund owned 4,287 shares of the conglomerate’s stock after selling 56 shares during the period. Phoenix Wealth Advisors’ holdings in Danaher were worth $984,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Decker Retirement Planning Inc. bought a new stake in shares of Danaher in the fourth quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America bought a new stake in shares of Danaher in the third quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher in the third quarter valued at approximately $40,000. FSA Wealth Management LLC bought a new stake in shares of Danaher in the third quarter valued at approximately $50,000. Finally, Darwin Wealth Management LLC bought a new stake in shares of Danaher in the third quarter valued at approximately $55,000. 79.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target for the company in a research note on Thursday, October 31st. Stephens restated an “overweight” rating and set a $315.00 target price on shares of Danaher in a research note on Wednesday, October 23rd. Raymond James cut their target price on Danaher from $300.00 to $275.00 and set an “outperform” rating for the company in a research note on Tuesday. TD Cowen upped their target price on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Finally, Evercore ISI upped their target price on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $285.55.

Danaher Stock Performance

NYSE DHR opened at $244.18 on Wednesday. The company has a market capitalization of $176.36 billion, a price-to-earnings ratio of 46.60, a PEG ratio of 4.30 and a beta of 0.83. Danaher Co. has a twelve month low of $225.42 and a twelve month high of $281.70. The stock has a fifty day simple moving average of $234.84 and a 200 day simple moving average of $253.53. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. Danaher’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period in the prior year, the business posted $2.02 earnings per share. Sell-side analysts expect that Danaher Co. will post 7.49 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. Danaher’s payout ratio is 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.